Tango Therapeutics, Inc. (TNGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Tango Therapeutics, Inc. on May 8, 2026, covering events occurring on May 7, 2026. The filing addresses the formalization of a separation agreement with a former executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and separation terms.
Material Changes
The primary material event is the departure of Daniella Beckman, who served as Chief Financial Officer, principal accounting officer, and principal financial officer. Her departure became effective on April 15, 2026. On May 7, 2026, the Company and Ms. Beckman executed a Separation Agreement and Release.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, market outlook, or general management commentary regarding the Company's business strategy. The document details the specific compensatory arrangements agreed upon for Ms. Beckman's separation:
- Severance Pay: Twelve months of base salary, paid in substantially equal installments over 12 months.
- Health Benefits: Reimbursement for monthly COBRA premium payments for up to 12 months.
- Equity Acceleration: Accelerated vesting of outstanding options and restricted stock units (RSUs) that would have vested had Ms. Beckman remained employed for an additional 24 months following May 1, 2026.
- Option Exercise Period: Extension of the post-termination exercise period for vested stock options through August 31, 2026.
- Condition: Receipt of these benefits is contingent upon Ms. Beckman executing a general release in favor of the Company.
Investor Verification Checklist
- Verify the total cash and equity value of the separation package by reviewing the attached Separation Agreement (Exhibit 10.1) and Ms. Beckman's prior employment agreement.
- Confirm the appointment of a new Chief Financial Officer and principal accounting officer to ensure continuity of financial reporting.
- Assess the impact of the accelerated equity vesting on the Company's share count and potential dilution.
- Review the Company's cash position to ensure it can support the 12-month severance and COBRA reimbursement obligations.